Current advances in Hodgkin’s lymphoma

Hodgkin’s lymphoma is a highly treatable malignancy. It has high cure rates yet there are many patients who relapse or are refractory to treatment. Traditionally, treatment has been with conventional chemotherapy; however, the development of brentuximab vedotin and immune checkpoint inhibitors has r...

Descripción completa

Detalles Bibliográficos
Autores principales: Vadakara, Joseph, Andrick, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Medical Association 2019
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450804/
https://www.ncbi.nlm.nih.gov/pubmed/30993260
http://dx.doi.org/10.1016/j.cdtm.2019.02.003
_version_ 1783409068445007872
author Vadakara, Joseph
Andrick, Benjamin
author_facet Vadakara, Joseph
Andrick, Benjamin
author_sort Vadakara, Joseph
collection PubMed
description Hodgkin’s lymphoma is a highly treatable malignancy. It has high cure rates yet there are many patients who relapse or are refractory to treatment. Traditionally, treatment has been with conventional chemotherapy; however, the development of brentuximab vedotin and immune checkpoint inhibitors has revolutionized the care of Hodgkin’s lymphoma. This is a review of the current advances in the management of Hodgkin’s lymphoma and a review of ongoing clinical trials in the field.
format Online
Article
Text
id pubmed-6450804
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Chinese Medical Association
record_format MEDLINE/PubMed
spelling pubmed-64508042019-04-16 Current advances in Hodgkin’s lymphoma Vadakara, Joseph Andrick, Benjamin Chronic Dis Transl Med Perspective Hodgkin’s lymphoma is a highly treatable malignancy. It has high cure rates yet there are many patients who relapse or are refractory to treatment. Traditionally, treatment has been with conventional chemotherapy; however, the development of brentuximab vedotin and immune checkpoint inhibitors has revolutionized the care of Hodgkin’s lymphoma. This is a review of the current advances in the management of Hodgkin’s lymphoma and a review of ongoing clinical trials in the field. Chinese Medical Association 2019-03-19 /pmc/articles/PMC6450804/ /pubmed/30993260 http://dx.doi.org/10.1016/j.cdtm.2019.02.003 Text en © 2019 Chinese Medical Association. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Perspective
Vadakara, Joseph
Andrick, Benjamin
Current advances in Hodgkin’s lymphoma
title Current advances in Hodgkin’s lymphoma
title_full Current advances in Hodgkin’s lymphoma
title_fullStr Current advances in Hodgkin’s lymphoma
title_full_unstemmed Current advances in Hodgkin’s lymphoma
title_short Current advances in Hodgkin’s lymphoma
title_sort current advances in hodgkin’s lymphoma
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450804/
https://www.ncbi.nlm.nih.gov/pubmed/30993260
http://dx.doi.org/10.1016/j.cdtm.2019.02.003
work_keys_str_mv AT vadakarajoseph currentadvancesinhodgkinslymphoma
AT andrickbenjamin currentadvancesinhodgkinslymphoma

Ejemplares similares